CA2446864A1 - Inhibitors of src and other protein kinases - Google Patents

Inhibitors of src and other protein kinases Download PDF

Info

Publication number
CA2446864A1
CA2446864A1 CA002446864A CA2446864A CA2446864A1 CA 2446864 A1 CA2446864 A1 CA 2446864A1 CA 002446864 A CA002446864 A CA 002446864A CA 2446864 A CA2446864 A CA 2446864A CA 2446864 A1 CA2446864 A1 CA 2446864A1
Authority
CA
Canada
Prior art keywords
iia
sch3
disease
optionally substituted
agent
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
CA002446864A
Other languages
French (fr)
Other versions
CA2446864C (en
Inventor
Young-Choon Moon
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Vertex Pharmaceuticals Inc
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2446864A1 publication Critical patent/CA2446864A1/en
Application granted granted Critical
Publication of CA2446864C publication Critical patent/CA2446864C/en
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
    • A61F9/00—Methods or devices for treatment of the eyes; Devices for putting-in contact lenses; Devices to correct squinting; Apparatus to guide the blind; Protective devices for the eyes, carried on the body or in the hand
    • A61F9/0008—Introducing ophthalmic products into the ocular cavity or retaining products therein
    • A61F9/0017—Introducing ophthalmic products into the ocular cavity or retaining products therein implantable in, or in contact with, the eye, e.g. ocular inserts
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A61K9/0051—Ocular inserts, ocular implants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
    • A61F2250/00—Special features of prostheses classified in groups A61F2/00 - A61F2/26 or A61F2/82 or A61F9/00 or A61F11/00 or subgroups thereof
    • A61F2250/0058—Additional features; Implant or prostheses properties not otherwise provided for
    • A61F2250/0067—Means for introducing or releasing pharmaceutical products into the body
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Abstract

The present invention provides compounds of formula I:wherein A is N or CR, and G, R1, R2, and R3 are as described in the specification. These compounds are inhibitors of protein kinase, particularly inhibitors of Src mammalian protein kinase involved in cell proliferation, cell death and response to extracellular stimuli. The invention also relates to methods for producing these inhibitors. The invention also provides pharmaceutical compositions comprising the inhibitors of the invention and methods of utilizing those compositions in the treatment and prevention of various disorders.

Claims (32)

1. A compound of formula I:

or a pharmaceutically acceptable derivative thereof, wherein:
G is -XR or -XAR;
each X is independently selected from a C1-6 alkylidene chain wherein one or two non-adjacent methylene units of X are independently replaced by -O-, -NR-, -S-,-C(O)-, -C(O)NR-, -NRC(O)-, -NRC(O)-, -SO-, -SO2-, -NRSO2-, -SO2NR-, -or -NRSO2NR-;
A is N or CR;
each R is independently selected from hydrogen or an optionally substituted C1-8 aliphatic group; or two R groups bound to the same nitrogen are taken together with the nitrogen to form a 3-7 membered heterocyclic ring having 0-2 heteroatoms, in addition to the nitrogen atom bound thereto, independently selected from nitrogen, oxygen, or sulfur; provided that when G is -N(R)2, the two R
groups are not taken together to form a ring;
Ar is an optionally substituted 5-6 membered saturated, partially unsaturated, or fully unsaturated monocyclic ring having zero to three heteroatoms independently selected from nitrogen, sulfur, or oxygen, or an optionally substituted 8-10 membered saturated, partially unsaturated, or fully unsaturated bicyclic ring having zero to four heteroatoms independently selected from nitrogen, sulfur, or oxygen;
R1 is T(n)-R or T (n)-Ar;
n is zero or one;
T is selected from -C(O)-, -CO2-, -C(O)C(O)-, -C (O) CH2C (O) -, -CONR-, -S (O) 2-, or -S (O)2NR-;
R2 is selected from hydrogen, Ar, or a C1-8 aliphatic group optionally substituted with 1-3 groups independently selected from oxo, OR, SR, SO2R, C (O) R, CO2R, CN, N (R)2, =N-OR, =NN (R) 2, =NNHC (O) R, =NNHCO2R, =NNHSO2R, Ar, NRC (O) N (R) 2, NRC (O) R, NRCO2R, C(O) N (R)2, SO2N (R)2, or NRSO2N(R)2; and R3 is selected from R or Ar.
2. The compound according to claim 1, wherein:
G is -X-R or -X-Ar, wherein:
each X is independently selected from a C1-4 alkylidene chain, wherein one or two non-adjacent methylene units of X are independently replaced by -S-, -SO-, -SO2-, -O-, or -NH-;
R is an optionally substituted C1-6 aliphatic group;
Ar is an optionally substituted 5-6 membered saturated or aryl ring having 0-2 heteroatoms independently selected from nitrogen, oxygen, or sulfur, or an optionally substituted 9-10 membered bicyclic aryl or heteroaryl ring having 0-2 heteroatoms independently selected from nitrogen, oxygen, or sulfur; and R3 is selected from 5-7 membered cyclic aliphatic or an optionally substituted 6 membered saturated, partially unsaturated, or fully unsaturated monocyclic ring having zero to three heteroatoms independently selected from nitrogen, sulfur, or oxygen.
3. The compound according to claim 2, wherein:
R is a C1-4 aliphatic group optionally substituted with halo, CN, oxo, N (R°) 2, OH, OR°, C(O)R°, C (O) N (R°) 2, NR°CO2R°, SR°, NR°SO2R°, SO2R°, NR°C (O) R°, OC (O) R°, or NR°C (O) N (R°) 2, wherein each R°
group is independently selected from hydrogen or C1-4 aliphatic;
Ar is an optionally substituted ring selected from phenyl, pyridyl, imidazolyl, thienyl, thiazolyl, [1,3.]dioxanyl, piperidinyl, morpholinyl, pyrrolyl, pyrrolidinyl, furanyl, tetrahydrofuranyl, pyranyl, imidazolyl, benzimidazolyl, pyrrolyl, piperazinyl, thiomorpholinyl, naphthyl, oxazolyl, triazinyl, tetrazolyl, dithiolanyl, dioxalanyl, benzofuranyl, benzothienyl, or indolyl; and R3 is selected from an optionally substituted cyclohexyl, cyclopentyl, phenyl, pyridyl, pyrimidinyl, or pyridazinyl ring.
4. The compound according to claim 2, wherein:
R2 is selected from R, CH2N (R) 2, or CH2Ar, wherein:
each R is independently selected from hydrogen or optionally substituted C1-4 aliphatic, and Ar is an optionally substituted 6 membered saturated or unsaturated ring having 0-2 heteroatoms independently selected from nitrogen, oxygen, or sulfur.
5. The compound according to claim 1, wherein:
R1 is T(n)-Ar, wherein n is zero; and Ar is selected from an optionally substituted 6-membered saturated or aryl ring having 0-2 nitrogens, or an optionally substituted 9-10 membered partially unsaturated or fully unsaturated bicyclic ring having 0-2 heteroatoms independently selected from nitrogen, oxygen, or sulfur.
6. The compound according to claim 5, wherein:
R1 is phenyl, cyclohexyl, pyridyl, naphthyl, quinolinyl, isoquinolinyl, or indanyl, wherein:
R1 is optionally substituted with 1-3 groups independently selected from R o, halogen, NO2, CN, OR o, SR o, N(R o)2, CO2R o, C(O)R o, CON(R o)2, phenyl, SO2R o, or NR o C(O)R o, wherein each R o is independently selected from hydrogen or an optionally substituted C1-4 aliphatic.
7. The compound according to claim 6, wherein R1 is optionally substituted with 1-3 groups independently selected from methyl, ethyl, oxo, CF3, OMe, C(O)Me, C(O)phenyl, CH=CH, CO2H, C(O)NH2, SMe, CO2Me, fluoro, SO2Me, NO2, CN, chloro, N(Me)2, NHC(O)Me, NH2, cyanophenyl, CO2Et, CH2OH, CH2OMe, 3 -CH2CO2H-phenyl , or 3 -CH2CH2CO2H-phenyl.
8. The compound according to claim 5, wherein:
R2 is selected from R, CH2N(R)2, or CH2Ar, wherein:
each R is independently selected from hydrogen or optionally substituted C1-4 aliphatic, and Ar is an optionally substituted 6 membered saturated or unsaturated ring having 0-2 heteroatoms independently selected from nitrogen, oxygen, or sulfur.
9. The compound according to claim 2, wherein said compound is selected from the following compounds:

No.~S-R~R2~R3~R4~R5~R6~R7 IIA-1 ~SCH3 Me ~Ph H~H H ~H
IIA-2 ~SCH3 Me Ph ~H ~H OMe H
IIA-3 ~SCH3 Me ~Ph H ~OMe ~OMe ~H
IIA-4 ~SCH3 Me ~Ph Me ~H ~H ~H
IIA-5 ~SCH3 Me ~Ph Me ~H CONH2 ~H
IIA-6 ~SCH3 Me ~Ph Me ~H ~CN ~H
IIA-7 ~SCH3 Me ~Ph H ~CN ~H ~H
IIA-8 ~SCH3 Me ~Ph Me ~F ~H ~H
IIA-9 ~SCH3 Me ~Ph Me ~H ~F ~H
IIA-10 ~SCH3 Me ~Ph CF3 ~H ~H ~H
IIA-11 ~SCH3 Et ~Ph H ~CN ~H ~H
IIA-12 ~SCH3 Et ~Ph H ~CO2H ~H ~H
IIA-13 ~SCH3 Me ~Ph H ~F ~H ~H
IIA-14 ~SCH3 Me ~Ph H ~H ~F ~H
IIA-15 ~SCH3 Me ~Ph H ~H ~COMe ~H
IIA-16 ~SCH3 Me ~Ph H ~H ~COPh ~H
IIA-17 ~SCH3 Me ~Ph H ~H ~CONH2 ~H
IIA-18 ~SCH3 Me ~Ph H ~OMe ~H ~OMe IIA-19 ~SCH3 Me ~Ph H ~F ~H ~H
IIA-20 ~SCH3 Me ~Ph H ~H ~CN ~H
IIA-21 ~SCH3 Me ~Ph H ~H ~COMB ~H
IIA-22 ~SCH3 Me ~Ph H ~CH=CH ~H ~H
IIA-23 ~SCH3 Me ~Ph H ~SMe ~H ~H
IIA-24 ~SCH3 Me ~Ph H ~Me ~CN ~H
IIA-25 ~SCH3 Me ~Ph H ~COME ~H ~H
IIA-26 ~SCH3 Et ~Ph H ~H ~H ~H
IIA-27 ~SCH3 Me ~Ph OMe ~H ~H ~H

No.~S-R~R2~R3~R4~R5~R6~R7 IIA-28 ~SCH3 Me ~Ph H ~H ~F ~H
IIA-29 ~SCH3 Me ~Ph H ~CO2H ~H ~H
IIA-30 ~SCH3 Me ~Ph H ~H ~Ph ~H
IIA-31 ~SCH3 Me ~Ph H ~Me ~H ~Me IIA-32 ~SCH3 Me ~Ph H ~H ~SMe ~H
IIA-33 ~SCH3 Me ~Ph H ~H ~OMe ~H
IIA-34 ~SCH3 Me ~Ph H ~OMe ~H ~H
IIA-35 ~SCH3 Me ~Ph OMe ~H ~H~CN
IIA-36 ~SCH3 Me ~Ph H ~CO2Me ~H ~H
IIA-37 ~SCH3 Me ~Ph F ~H ~H~CN
IIA-38 ~SCH3 Me ~Ph H~H ~H ~H
IIA-39 ~SCH3 Me ~Ph H ~H ~CO2H~H
IIA-40 ~SCH3 Me ~Ph Me ~H ~CN ~H
IIA-41 ~SCH3 Me ~Ph F ~H ~F ~H
IIA-42 ~SCH3 Me ~Ph Me ~H CONH2 ~H
IIA-43 ~SCH3 Me ~Ph Me ~Cl ~H ~H
IIA-44 ~SCH3 Me ~Ph F ~H ~H ~H
IIA-45 ~SCH3 Me ~Ph Me ~H ~OMe ~H
IIA-46 ~SCH3 Me ~Ph OMe ~H ~H ~H
IIA-47 ~SCH3 Me ~Ph H ~H ~SO2Me ~H
IIA-48 ~SCH3 Me ~Ph H ~H ~CO2Me ~H
IIA-49 ~SCH3 Me ~Ph NO2 ~H ~H ~H
IIA-50 ~SCH3 Me ~Ph H ~CN ~H ~H
IIA-51 ~SCH3 Me ~Ph H ~H ~CN ~H
IIA-52 ~SCH3 Me ~Ph CHCH ~H ~H ~H
IIA-53 ~SCH3 Me ~Ph Me ~F ~H ~H
IIA-54 ~SCH3 Me ~Ph Cl ~H ~H ~OMe IIA-55 ~SCH3 Me ~Ph H ~Me ~OMe ~H
IIA-56 ~SCH3 Me ~Ph Me ~H ~F ~H
IIA-57 ~SCH3 Me ~Ph SMe ~H ~H ~H
IIA-58 ~SCH3 Me ~Ph OMe ~H ~H ~OMe IIA-59 ~SCH2CH3 Me ~Ph H ~H ~H ~H
IIA-60 ~SCH2CH3 Me ~Ph H ~CN ~H ~H
IIA-61 ~SCH2CH3 Me ~Ph H ~H ~CN ~H
IIA-62~SCH2CH3 Me ~Ph H ~F ~H ~H

No.~S-R~~R2~R3~R4~R5~R6~R7 IIA-63 ~SCH2CH3 ~Me ~Ph H ~H ~F ~H
IIA-64 ~SCH2CH3 ~Me ~Ph H ~Me ~CN ~H
IIA-65 ~SCH2CH3 ~Me ~Ph H ~F ~CN ~H
IIA-66 ~SCH2CH3 ~Me ~Ph H ~H ~SMe ~H
IIA-67 ~SCH(CH3)2 ~Me ~Ph H ~H ~H ~H
IIA-68 ~SCH2CH(CH3)2 ~Me ~Ph H ~H ~H ~H
IIA-69 ~S-propyl Me ~Ph H ~H ~H ~H
IIA-70 ~S-butyl ~Me ~Ph H ~H ~H ~H
IIA-71 ~S-pentyl ~Me ~Ph H ~H ~H ~H
IIA-72 ~S-hexyl ~Me ~Ph H ~H ~H ~H
IIA-73 ~S-heptyl ~Me ~Ph H ~H ~H ~H
IIA-74 ~S-octyl ~Me ~Ph H ~H ~H ~H
IIA-75 ~SCH2CN ~Me ~Ph H ~H ~H ~H
IIA-76 SCH2CH2OCH3 ~Me ~Ph H ~H ~H ~H
IIA-77 ~SCH2CH2CF3 ~Me ~Ph H ~H ~H ~H
IIA-78 ~SCH2(cyclopropyl) Me Ph H ~H ~H ~H
IIA-79 ~SCH2C(=O)CH3 ~Me ~Ph H ~H ~H ~H
IIA-80 ~SCH2CH2N(CH3)2 Me ~Ph H ~H ~H ~H
IIA-81 ~SCH2CH2NHCOCH3 ~Me ~Ph H ~H ~H ~H
IIA-82 ~SCH2CH2NHCO2CH3~Me ~Ph H ~H ~H ~H
IIA-83 ~SCH2CH2OC(=O)CH3 Me ~Ph H ~H ~H ~H
IIA-84 SCH2CH(NH2)CO2Et Me ~Ph H ~H ~H ~H
IIA-85 ~SCH2C.ident.CCH3 Me ~Ph H ~H ~H ~H
IIA-86 ~S-propyl Me ~Ph H ~H COMe ~H
IIA-87 ~S-propyl ~ Me ~Ph H ~CN ~H ~H
IIA-88 ~S-propyl Me ~Ph H ~H ~CN ~H~
IIA-89 ~S-propyl Me ~Ph H ~F ~H ~H
IIA-90 ~S-propyl Me ~Ph H ~H ~F ~H
IIA-91 ~S-propyl Me ~Ph H ~CN ~F ~H
IIA-92 ~S-propyl Me ~Ph H ~H ~SMe ~H
IIA-93 ~SCH3 Me ~Ph H ~H ~NMe2 ~H
IIA-94 ~SCH3 Me ~Ph H ~NO2 ~H ~H
IIA-95 ~SCH3 Me ~Ph H ~NHAc ~H ~H
IIA-96 ~SCH3 ~ Me ~Ph H ~NH2 ~H ~H
IIA-97 ~SCH3 Me ~Ph H ~Me ~H ~H

No. S-R R2 R3 R4 R5 R6 R7 IIA-127 SCH3 Me Ph H Cl H H

IIA-128 SCH3 Me 2-Pyr H H OCH2Ph H

IIA-129 CH2CH2SCH Me Ph H OCH2Ph H H

IIA-130 CH2CH2SCH3 Me Ph H OPh H H

IIA-131 CH2CH2SCH Me Ph H Cl H H

IIA-132 CH2CH2SCH3 Me Ph H OMe H H

IIA-133 CH2CH2SCH3 Me Ph H CO2CH3 H H

IIA-134 SCH3 Me Ph H OH H H.
10. The compound according to claim 5, wherein said compound is selected from the following compounds:

11. The compound according to claim 8, wherein said compound is selected from the following compounds:

No. R2 IIA-156 CH2(morpholin-4-yl) IIA-157 CH2N(CH3)2 IIA-158 CH2NEt2 IIA-159 CH2N(CH3)CH2Ph IIA-160 CH2N(CH3)CH2CO2CH3 IIA-161 CH2(piperazin-1-yl).
12. The compound according to claim 2, wherein said compound is selected from the following compounds:

13. The compound according to claim 2, wherein said compound is selected from the following compounds:

No. G A R1 R2 IC-1 -NH-ethyl CH phenyl CH3 IC-2 -NH-propyl N phenyl CH3 IC-3 -NH-butyl N 3-CN-phenyl CH3 IC-4 -NH-isobutyl N phenyl CH3 IC-5 -NH-CH2CH2N(CH3)2 N 3-OCH3-phenyl CH3
14. A composition comprising a compound according to claim 1 in an amount to detectably inhibit JNK3, Lck, or Src kinase activity, and a pharmaceutically acceptable carrier, adjuvant, or vehicle.
15. The composition according to claim 14, additionally comprising an additional therapeutic agent selected from an anti-proliferative agent, an anti-inflammatory agent, an immunomodulatory agent, a neurotrophic factor, an agent for treating cardiovascular disease, an agent for treating liver disease, an anti-viral agent, an agent for treating blood disorders, an agent for treating diabetes, or an agent for treating immunodeficiency disorders.
16. A method of inhibiting JNK3, Lck, or Src kinase activity in a biological sample comprising the step of contacting said biological sample with:

a) a compound according to claim 1; or b) a composition according to claim 14.
17. A method of treating or lessening the severity of a JNK3-, Lck-, or Src-mediated disease or condition in a patient comprising the step of administering to said patient a composition according to claim 14.
18. A method of treating or lessening the severity of an inflammatory disease, autoimmune disease, destructive bone disorder, proliferative disorder, infectious disease, neurodegenerative disease, allergy, reperfusion/ischemia in stroke, heart attack, angiogenic disorder, organ hypoxia, vascular hyperplasia, cardiac hypertrophy, thrombin-induced platelet aggregation or a condition associated with proinflammatory cytokines comprising the step of administering to said patient a composition according to claim 14.
19. The method according to claim 18, wherein said method is used to treat or prevent an inflammatory disease selected from acute pancreatitis, chronic pancreatitis, asthma, allergies, or adult respiratory distress syndrome.
20. The method according to claim 18, wherein said.
method is used to treat or prevent an autoimmune disease selected from glomerulonephritis, rheumatoid arthritis, systemic lupus erythematosus, scleroderma, chronic thyroiditis, Graves' disease, autoimmune gastritis, diabetes, autoimmune hemolytic anemia, autoimmune neutropenia, thrombocytopenia, atopic dermatitis, chronic active hepatitis, myasthenia gravis, multiple sclerosis, inflammatory bowel disease, ulcerative colitis, Crohn's disease, psoriasis, or graft vs. host disease.
21. The method according to claim 18, wherein said method is used to treat or prevent a destructive bone disorders selected from osteoarthritis, osteoporosis or multiple myeloma-related bone disorder.
22. The method according to claim 18, wherein said method is used to treat or prevent a proliferative disease selected from acute myelogenous leukemia, chronic myelogenous leukemia, metastatic melanoma, Kaposi's sarcoma, or multiple myeloma.
23. The method according to claim 18, wherein said method is used to treat or prevent neurodegenerative disease selected from Alzheimer's disease, Parkinson's disease, amyotrophic lateral sclerosis, Huntington's disease, cerebral ischemia or neurodegenerative disease caused by traumatic injury, glutamate neurotoxicity or hypoxia.
24. The method according to claim 18, wherein said method is used to treat or prevent ischemia/reperfusion in stroke or myocardial ischemia, renal ischemia, heart attacks, organ hypoxia or thrombin-induced platelet aggregation.
25. The method according to claim 18, wherein said method is used to treat or prevent a condition associated with T-cell activation or pathologic immune responses.
26. The method according to claim 18, wherein said method is used to treat or prevent an angiogenic disorder selected from solid tumors, ocular neovasculization, or infantile haemangiomas.
27. The method according to claim 17, wherein said disease is selected from hypercalcemia, restenosis, hypercalcemia, osteoporosis, osteoarthritis, symptomatic treatment of bone metastasis, rheumatoid arthritis, inflammatory bowel disease, multiple sclerosis, psoriasis, lupus, graft vs. host disease, T-cell mediated hypersensitivity disease, Hashimoto's thyroiditis, Guillain-Barre syndrome, chronic obtructive pulmonary disorder, contact dermatitis, cancer, Paget's disease, asthma, ischemic or reperfusion injury, allergic disease, atopic dermatitis, or allergic rhinitis.
28. The method according to claim 27, wherein said disease is selected from hypercalcemia, osteoperosis, osteoarthritis, or sympomatic treatment of bone metastasis.
29. The method according to claim 17, wherein said disease is selected from autoimmune diseases, allergies, rheumatoid arthritis, and leukemia.
30. The method according to claim 17, comprising the additional step of administering to said patient an additional therapeutic agent selected from an anti-proliferative agent, an anti-inflammatory agent, an immunomodulatory agent, a neurotrophic factor, an agent for treating cardiovascular disease, an agent for treating liver disease, an anti-viral agent, an agent for treating blood disorders, an agent for treating diabetes, or an agent for treating immunodeficiency disorders, wherein:

said additional therapeutic agent is appropriate for the disease being treated; and said additional therapeutic agent is administered together with said composition as a single dosage form or separately from said composition as part of a multiple dosage form.
31. A composition for coating an implantable device comprising a compound according to claim 1 and a carrier suitable for coating said implantable device.
32. An implantable device coated with a composition according to claim 31.
CA2446864A 2001-05-16 2002-05-16 Inhibitors of src and other protein kinases Expired - Fee Related CA2446864C (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US29134001P 2001-05-16 2001-05-16
US60/291,355 2001-05-16
PCT/US2002/015606 WO2002092573A2 (en) 2001-05-16 2002-05-16 Heterocyclic substituted pyrazoles as inhibitors of src and other protein kinases

Publications (2)

Publication Number Publication Date
CA2446864A1 true CA2446864A1 (en) 2002-11-21
CA2446864C CA2446864C (en) 2011-02-15

Family

ID=23119908

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2446864A Expired - Fee Related CA2446864C (en) 2001-05-16 2002-05-16 Inhibitors of src and other protein kinases

Country Status (6)

Country Link
US (1) US6884804B2 (en)
EP (1) EP1404669A2 (en)
JP (1) JP4316893B2 (en)
AU (1) AU2002308748A1 (en)
CA (1) CA2446864C (en)
WO (1) WO2002092573A2 (en)

Families Citing this family (138)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2001291013A1 (en) 2000-09-15 2002-03-26 Vertex Pharmaceuticals Incorporated Pyrazole compounds useful as protein kinase inhibitors
US6660731B2 (en) * 2000-09-15 2003-12-09 Vertex Pharmaceuticals Incorporated Pyrazole compounds useful as protein kinase inhibitors
US7473691B2 (en) * 2000-09-15 2009-01-06 Vertex Pharmaceuticals Incorporated Pyrazole compounds useful as protein kinase inhibitors
AU2001297619B2 (en) 2000-12-21 2006-06-08 Vertex Pharmaceuticals Incorporated Pyrazole compounds useful as protein kinase inhibitors
CA2446756C (en) * 2001-06-01 2011-03-08 Vertex Pharmaceuticals Incorporated Thiazole compounds useful as inhibitors of protein kinase
GB0129476D0 (en) * 2001-12-10 2002-01-30 Syngenta Participations Ag Organic compounds
AU2003235741B8 (en) * 2002-01-07 2009-01-15 Eisai R&D Management Co., Ltd. Deazapurines and uses thereof
ES2437391T3 (en) * 2002-02-06 2014-01-10 Vertex Pharmaceuticals, Inc. Heteroaryl compounds useful as GSK-3 inhibitors
US8623822B2 (en) 2002-03-01 2014-01-07 Bracco Suisse Sa KDR and VEGF/KDR binding peptides and their use in diagnosis and therapy
US7261876B2 (en) 2002-03-01 2007-08-28 Bracco International Bv Multivalent constructs for therapeutic and diagnostic applications
US7794693B2 (en) 2002-03-01 2010-09-14 Bracco International B.V. Targeting vector-phospholipid conjugates
US20050100963A1 (en) 2002-03-01 2005-05-12 Dyax Corporation KDR and VEGF/KDR binding peptides and their use in diagnosis and therapy
WO2003076434A1 (en) 2002-03-09 2003-09-18 Astrazeneca Ab 4- imidazolyl substuited pyrimidine derivatives with cdk inhibitiory activity
GB0205693D0 (en) 2002-03-09 2002-04-24 Astrazeneca Ab Chemical compounds
GB0205690D0 (en) 2002-03-09 2002-04-24 Astrazeneca Ab Chemical compounds
DE60332604D1 (en) * 2002-03-15 2010-07-01 Vertex Pharma AZOLYLAMINOAZINE AS PROTEIN KINASE INHIBITOR
US6677337B2 (en) * 2002-03-19 2004-01-13 The Procter & Gamble Company 1,2-dihydropyrazol-3-ones which controls inflammatory cytokines
MY141867A (en) * 2002-06-20 2010-07-16 Vertex Pharma Substituted pyrimidines useful as protein kinase inhibitors
CA2494100C (en) * 2002-08-02 2011-10-11 Vertex Pharmaceuticals Incorporated Pyrazole compositions useful as inhibitors of gsk-3
WO2004072029A2 (en) * 2003-02-06 2004-08-26 Vertex Pharmaceuticals Incorporated Pyrazolopyridazines useful as inhibitors of protein kinases
DE602004028800D1 (en) * 2003-02-07 2010-10-07 Daiichi Sankyo Co Ltd Pyrazolderivat
GB0311274D0 (en) 2003-05-16 2003-06-18 Astrazeneca Ab Chemical compounds
GB0311276D0 (en) 2003-05-16 2003-06-18 Astrazeneca Ab Chemical compounds
WO2005040135A1 (en) * 2003-10-24 2005-05-06 Ono Pharmaceutical Co., Ltd. Antistress drug and medical use thereof
US7592340B2 (en) * 2003-12-04 2009-09-22 Vertex Pharmaceuticals Incorporated Quinoxalines useful as inhibitors of protein kinases
TW200528101A (en) 2004-02-03 2005-09-01 Astrazeneca Ab Chemical compounds
WO2005105780A2 (en) * 2004-04-28 2005-11-10 Vertex Pharmaceuticals Incorporated Compositions useful as inhibitors of rock and other protein kinases
WO2005118543A1 (en) * 2004-06-03 2005-12-15 Ono Pharmaceutical Co., Ltd. Kinase inhibitor and use thereof
KR101246863B1 (en) * 2004-06-04 2013-03-25 바이오니취 라이프 사이언시즈 인코포레이티드 Use of imatinib to treat liver disorders and viral infections
AU2005254982B2 (en) * 2004-06-10 2008-11-27 Irm Llc Compounds and compositions as protein kinase inhibitors
ES2396421T3 (en) * 2004-08-27 2013-02-21 Laboratorios Del Dr. Esteve, S.A. Sigma receptor inhibitors
EP1634872A1 (en) * 2004-08-27 2006-03-15 Laboratorios Del Dr. Esteve, S.A. Pyrazole derivatives as sigma receptor inhibitors
BRPI0514692A (en) * 2004-08-27 2008-06-17 Esteve Labor Dr sigma receptor inhibitors
ES2251316B1 (en) * 2004-10-14 2007-03-16 Laboratorios Del Dr. Esteve, S.A. SIGMA RECEIVER INHIBITORS.
CA2580913A1 (en) * 2004-10-13 2006-04-27 Wyeth N-benzenesulfonyl substituted anilino-pyrimidine analogs
AU2005306458B2 (en) * 2004-11-17 2011-02-17 Miikana Therapeutics, Inc. Kinase inhibitors
DE102008020113A1 (en) 2008-04-23 2009-10-29 Bayer Schering Pharma Aktiengesellschaft Substituted dihydropyrazolones and their use
CN1939910A (en) * 2004-12-31 2007-04-04 孙飘扬 Amino-metadiazine compound and its salt, its preparation and pharmaceutical use
DE102005019712A1 (en) 2005-04-28 2006-11-09 Bayer Healthcare Ag Dipyridyl-dihydropyrazolone and its use
EP1917259B1 (en) * 2005-08-18 2012-01-25 Vertex Pharmaceuticals Incorporated Pyrazine kinase inhibitors
KR20140025610A (en) * 2005-09-30 2014-03-04 미카나 테라퓨틱스, 인크. Substituted pyrazole compounds
CN103145702A (en) * 2005-11-03 2013-06-12 顶点医药品公司 Aminopyrimidines useful as kinase inhibitors
TW201434835A (en) 2005-12-13 2014-09-16 Incyte Corp Heteroaryl substituted pyrrolo[2,3-b]pyridines and pyrrolo[2,3-b]pyrimidines as janus kinase inhibitors
WO2007089688A2 (en) 2006-01-31 2007-08-09 The University Of Toledo Na/k-atpase ligand
EP1829875A1 (en) 2006-03-01 2007-09-05 Laboratorios Del Dr. Esteve, S.A. Pyrazole derivatives as sigma receptor inhibitors
EP1829866A1 (en) * 2006-03-02 2007-09-05 Laboratorios Del Dr. Esteve, S.A. Sigma receptor inhibitors
EP1829867A1 (en) * 2006-03-03 2007-09-05 Laboratorios Del Dr. Esteve, S.A. Imidazole compounds having pharmaceutical activity towards the sigma receptor
DE102006050515A1 (en) 2006-10-26 2008-04-30 Bayer Healthcare Ag New substituted dipyridiyl-dihydropyrazolone derivatives are hypoxia-inducible transcription factor-prolyl-4-hydroxylase inhibitors useful to treat/prevent e.g. cardiovascular diseases, heart-circulation diseases, heart failure and anemia
DE102006050516A1 (en) 2006-10-26 2008-04-30 Bayer Healthcare Ag New pyrazol-3-one compounds are hypoxia-inducible transcription factor-prolyl-4-hydroxylase inhibitors useful e.g. to treat and/or prophylaxis heart-circulation diseases, heart failure, anemia, chronic kidney diseases and renal failure
DE102006050513A1 (en) 2006-10-26 2008-04-30 Bayer Healthcare Ag New substituted dihydropyrazolone derivatives are hypoxia-inducible transcription factor-prolyl-4-hydroxylase inhibitors useful to treat/prevent e.g. cardiovascular diseases, heart-circulation diseases, heart failure and anemia
CA2667251C (en) * 2006-10-31 2018-05-29 University Of Toledo Na+/k+-atpase-specific peptide inhibitors/activators of src and src family kinases
DE602007004750D1 (en) * 2006-11-02 2010-03-25 Vertex Pharma AS INHIBITORS OF PROTEIN KINASES SUITABLE AMINOPYRIDINES AND AMINOPYRIMIDINES
WO2008060535A2 (en) * 2006-11-10 2008-05-22 Dana-Farber Cancer Institute, Inc. Use of reversine and analogs for treatment of cancer
AU2007324850A1 (en) * 2006-11-27 2008-06-05 Ares Trading S.A. Treatment for multiple myeloma
ES2347721T3 (en) * 2006-12-19 2010-11-03 Vertex Pharmaceuticals, Inc. USEFUL AMINOPIRIMIDINS AS PROTEIN QUINASE INHIBITORS.
NZ579485A (en) * 2007-03-09 2012-02-24 Vertex Pharma Aminopyrimidines useful as inhibitors of protein kinases
EP2134707B1 (en) * 2007-03-09 2013-09-11 Vertex Pharmaceuticals, Inc. Aminopyrimidines useful as inhibitors of protein kinases
NZ579483A (en) 2007-03-09 2012-07-27 Vertex Pharma Aminopyridines useful as inhibitors of protein kinases
WO2008128009A2 (en) 2007-04-13 2008-10-23 Vertex Pharmaceuticals Incorporated Aminopyrimidines useful as kinase inhibitors
MX2009011812A (en) * 2007-05-02 2010-01-14 Vertex Pharma Aminopyrimidines useful as kinase inhibitors.
MX2009011811A (en) * 2007-05-02 2010-01-14 Vertex Pharma Aminopyrimidines useful as kinase inhibitors.
CA2685876A1 (en) 2007-05-02 2008-11-13 Vertex Pharmaceuticals Incorporated Thiazoles and pyrazoles useful as kinase inhibitors
AU2008257044A1 (en) * 2007-05-24 2008-12-04 Vertex Pharmaceuticals Incorporated Thiazoles and pyrazoles useful as kinase inhibitors
JP2010529193A (en) * 2007-06-11 2010-08-26 ミイカナ セラピューティクス インコーポレイテッド Substituted pyrazole compounds
LT3070090T (en) 2007-06-13 2019-06-25 Incyte Holdings Corporation Use of salts of the janus kinase inhibitor (r)-3-(4-(7h-pyrrolo[2,3-d]pyrimidin-4-yl)-1h- pyrazol-1-yl)-3- cyclopentylpropanenitrile
JP5553751B2 (en) * 2007-07-31 2014-07-16 バーテックス ファーマシューティカルズ インコーポレイテッド Process for preparing 5-fluoro-1H-pyrazolo [3,4-b] pyridin-3-amine and its derivatives
CN101815712A (en) * 2007-08-01 2010-08-25 辉瑞有限公司 Pyrazole compound and as the purposes of RAF inhibitor
NZ585139A (en) * 2007-11-16 2012-05-25 Incyte Corp 4-pyrazolyl-n-arylpyrimidin-2-amines and 4-pyrazolyl-n-heteroarylpyrimidin-2-amines as jak inhibitors
PT2231636E (en) * 2007-12-07 2012-01-02 Novartis Ag Pyrazole derivatives and use thereof as inhibitors of cyclin dependent kinases
EP2116539A1 (en) 2008-04-25 2009-11-11 Laboratorios Del. Dr. Esteve, S.A. 1-aryl-3-aminoalkoxy-pyrazoles as sigma ligands enhancing analgesic effects of opioids and attenuating the dependency thereof
AU2009288200A1 (en) * 2008-09-03 2010-03-11 Vertex Pharmaceuticals Incorporated Co-crystals and pharmaceutical formulations comprising the same
CL2009001884A1 (en) * 2008-10-02 2010-05-14 Incyte Holdings Corp Use of 3-cyclopentyl-3- [4- (7h-pyrrolo [2,3-d] pyrimidin-4-yl) -1h-pyrazol-1-yl) propanonitrile, janus kinase inhibitor, and use of a composition that understands it for the treatment of dry eye.
PT2432472T (en) 2009-05-22 2019-12-09 Incyte Holdings Corp 3-[4-(7h-pyrrolo[2,3-d]pyrimidin-4-yl)-1h-pyrazol-1-yl]octane- or heptane-nitrile as jak inhibitors
KR101771401B1 (en) * 2009-05-22 2017-08-25 인사이트 홀딩스 코포레이션 N-(HETERO)ARYL-PYRROLIDINE DERIVATIVES OF PYRAZOL-4-YL-PYRROLO[2,3-d]PYRIMIDINES AND PYRROL-3-YL-PYRROLO[2,3-d]PYRIMIDINES AS JANUS KINASE INHIBITORS
WO2011028685A1 (en) 2009-09-01 2011-03-10 Incyte Corporation Heterocyclic derivatives of pyrazol-4-yl-pyrrolo[2,3-d]pyrimidines as janus kinase inhibitors
EP2475667A1 (en) * 2009-09-10 2012-07-18 F. Hoffmann-La Roche AG Inhibitors of jak
ES2555252T3 (en) 2009-09-16 2015-12-30 The University Of Toledo Na / K-ATPase ligands, ouabain antagonists, assays and use thereof
US8691947B2 (en) 2010-01-13 2014-04-08 The University Of Toledo Materials related to sodium/potassium adenosine triphosphatase and Src
EP2353598A1 (en) 2010-02-04 2011-08-10 Laboratorios Del. Dr. Esteve, S.A. Sigma ligands for use in the prevention and/or treatment of postoperative pain
EP2353591A1 (en) 2010-02-04 2011-08-10 Laboratorios Del. Dr. Esteve, S.A. Sigma ligands for potentiating the analgesic effect of opioids and opiates in post-operative pain and attenuating the dependency thereof
CN102844317B (en) * 2010-02-18 2015-06-03 因西特公司 Cyclobutane and methylcyclobutane derivatives as janus kinase inhibitors
EP2545045B1 (en) 2010-03-10 2016-01-06 Incyte Holdings Corporation Piperidin-4-yl azetidine derivatives as jak1 inhibitors
CA2829790C (en) 2010-03-30 2018-06-05 Verseon Corporation Multisubstituted aromatic compounds as inhibitors of thrombin
EA035981B1 (en) 2010-05-21 2020-09-09 Инсайт Холдингс Корпорейшн Jak inhibitor formulation for topical application
EP2388005A1 (en) 2010-05-21 2011-11-23 Laboratorios Del. Dr. Esteve, S.A. Sigma ligands for the prevention and/or treatment of emesis induced by chemotherapy or radiotherapy
EP2395003A1 (en) 2010-05-27 2011-12-14 Laboratorios Del. Dr. Esteve, S.A. Pyrazole compounds as sigma receptor inhibitors
RS54865B1 (en) 2010-06-04 2016-10-31 Hoffmann La Roche Aminopyrimidine derivatives as lrrk2 modulators
EP2415471A1 (en) 2010-08-03 2012-02-08 Laboratorios Del. Dr. Esteve, S.A. Use of sigma ligands in opioid-induced hyperalgesia
PT3124483T (en) 2010-11-10 2019-10-02 Genentech Inc Pyrazole aminopyrimidine derivatives as lrrk2 modulators
DE102010044131A1 (en) 2010-11-18 2012-05-24 Bayer Schering Pharma Aktiengesellschaft Substituted sodium 1H-pyrazole-5-olate
WO2012068440A1 (en) 2010-11-19 2012-05-24 Incyte Corporation Heterocyclic-substituted pyrrolopyridines and pyrrolopyrimidines as jak inhibitors
TW201249845A (en) 2010-11-19 2012-12-16 Incyte Corp Cyclobutyl substituted pyrrolopyridine and pyrrolopyrimidine derivatives as JAK inhibitors
JPWO2012102387A1 (en) * 2011-01-27 2014-07-03 日産化学工業株式会社 Pyrazole derivatives and pest control agents
ES2547916T3 (en) 2011-02-18 2015-10-09 Novartis Pharma Ag MTOR / JAK inhibitor combination therapy
EP2524694A1 (en) 2011-05-19 2012-11-21 Laboratorios Del. Dr. Esteve, S.A. Use of sigma ligands in diabetes type-2 associated pain
ES2560611T3 (en) 2011-06-20 2016-02-22 Incyte Holdings Corporation Phenyl azetidinyl, pyridyl or pyrazinyl carboxamide derivatives as JAK inhibitors
US9358229B2 (en) 2011-08-10 2016-06-07 Novartis Pharma Ag JAK PI3K/mTOR combination therapy
TW201313721A (en) 2011-08-18 2013-04-01 Incyte Corp Cyclohexyl azetidine derivatives as JAK inhibitors
UA111854C2 (en) 2011-09-07 2016-06-24 Інсайт Холдінгс Корпорейшн METHODS AND INTERMEDIATE COMPOUNDS FOR JAK INHIBITORS
JP2015503504A (en) * 2011-12-23 2015-02-02 ミレニアム ファーマシューティカルズ， インコーポレイテッドＭｉｌｌｅｎｎｉｕｍ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ， Ｉｎｃ． Heteroaryl and uses thereof
US8853248B2 (en) * 2012-04-05 2014-10-07 Hubert Maehr (1,2,3-triazolyl)sulfonyl derivatives
NZ731797A (en) 2012-04-24 2018-08-31 Vertex Pharma Dna-pk inhibitors
TW201406761A (en) 2012-05-18 2014-02-16 Incyte Corp Piperidinylcyclobutyl substituted pyrrolopyridine and pyrrolopyrimidine derivatives as JAK inhibitors
CN105007901A (en) 2012-11-15 2015-10-28 因赛特公司 Sustained-release dosage forms of ruxolitinib
TWI634121B (en) 2013-03-06 2018-09-01 英塞特控股公司 Processes and intermediates for making a jak inhibitor
ES2900061T3 (en) 2013-03-12 2022-03-15 Vertex Pharma DNA-PK inhibitors
BR112015023214A8 (en) 2013-03-15 2019-12-24 Verseon Corp compound, pharmaceutical composition, and, use of a pharmaceutical compound or composition
SG10201707480PA (en) 2013-03-15 2017-10-30 Verseon Corp Multisubstituted aromatic compounds as serine protease inhibitors
TWI822248B (en) 2013-08-07 2023-11-11 美商英塞特控股公司 Sustained release dosage forms for a jak1 inhibitor
DK3424920T3 (en) 2013-10-17 2020-06-08 Vertex Pharma CO CRYSTALS OF (S) -N-METHYL-8- (1 - ((2'-METHYL- [4,5'-BIPYRIMIDIN] -6-YL) AMINO) PROPAN-2-YL) QUINOLIN-4-CARBOXAMIDE AND DEUTERATED DERIVATIVES THEREOF AS DNA-PK INHIBITORS
TN2016000228A1 (en) 2013-12-17 2017-10-06 Esteve Labor Dr SEROTONIN-NOREPINEPHRINE REUPTAKE INHIBITORS (SNRIs) AND SIGMA RECEPTOR LIGANDS COMBINATIONS.
US9498467B2 (en) 2014-05-30 2016-11-22 Incyte Corporation Treatment of chronic neutrophilic leukemia (CNL) and atypical chronic myeloid leukemia (aCML) by inhibitors of JAK1
CN108064274A (en) 2014-07-30 2018-05-22 耶达研究及发展有限公司 For cultivating the culture medium of multipotential stem cell
BR112017004704A2 (en) 2014-09-17 2018-01-23 Verseon Corp compound, pharmaceutical composition, and method for treating a disease or disorder in an individual
LT3261639T (en) 2015-02-27 2022-11-25 Verseon International Corporation Substituted pyrazole compounds as serine protease inhibitors
KR20180043794A (en) * 2015-08-04 2018-04-30 이섬 리서치 디벨러프먼트 컴파니 오브 더 히브루 유니버시티 오브 예루살렘 엘티디. Pyrazolpyimidine derivatives and uses thereof
EP3228630A1 (en) 2016-04-07 2017-10-11 IMBA-Institut für Molekulare Biotechnologie GmbH Combination of an apelin antagonist and an angiogenesis inhibitor for the treatment of cancer
ES2700448R1 (en) * 2016-06-07 2019-02-26 Esteve Pharmaceuticals Sa USE OF SIGMA RECEIVER LIGANDS IN DIABETES AND THE METABOLIC SYNDROME
AU2017335648B2 (en) 2016-09-27 2022-02-17 Vertex Pharmaceuticals Incorporated Method for treating cancer using a combination of DNA-damaging agents and DNA-PK inhibitors
CN106580967A (en) * 2017-02-17 2017-04-26 刘琨 Medicine composition for treating KOA (knee osteoarthritis)
WO2019070742A1 (en) * 2017-10-03 2019-04-11 Sidecar Therapeutics, Inc. Apoptosis signal-regulating kinase 1 (ask 1) inhibitor compounds
US10596161B2 (en) 2017-12-08 2020-03-24 Incyte Corporation Low dose combination therapy for treatment of myeloproliferative neoplasms
MD3746429T2 (en) 2018-01-30 2022-08-31 Incyte Corp Processes for preparing (1-(3-fluoro-2-(trifluoromethyl)isonicotinyl)piperidine-4-one)
CN113768927A (en) 2018-03-30 2021-12-10 因赛特公司 Treatment of hidradenitis suppurativa with JAK inhibitors
US11066404B2 (en) 2018-10-11 2021-07-20 Incyte Corporation Dihydropyrido[2,3-d]pyrimidinone compounds as CDK2 inhibitors
WO2020152686A1 (en) 2019-01-23 2020-07-30 Yeda Research And Development Co. Ltd. Culture media for pluripotent stem cells
US11384083B2 (en) 2019-02-15 2022-07-12 Incyte Corporation Substituted spiro[cyclopropane-1,5′-pyrrolo[2,3-d]pyrimidin]-6′(7′h)-ones as CDK2 inhibitors
WO2020180959A1 (en) 2019-03-05 2020-09-10 Incyte Corporation Pyrazolyl pyrimidinylamine compounds as cdk2 inhibitors
WO2020205560A1 (en) 2019-03-29 2020-10-08 Incyte Corporation Sulfonylamide compounds as cdk2 inhibitors
WO2020223558A1 (en) 2019-05-01 2020-11-05 Incyte Corporation Tricyclic amine compounds as cdk2 inhibitors
US11440914B2 (en) 2019-05-01 2022-09-13 Incyte Corporation Tricyclic amine compounds as CDK2 inhibitors
WO2020259683A1 (en) * 2019-06-28 2020-12-30 成都赜灵生物医药科技有限公司 2,4-disubstituted pyrimidine derivative, preparation method for same, and uses thereof
CN112142731B (en) * 2019-06-28 2022-07-22 成都赜灵生物医药科技有限公司 2, 4-disubstituted pyrimidine derivative and preparation method and application thereof
CN116348458A (en) 2019-08-14 2023-06-27 因赛特公司 Imidazolylpyrimidinylamine compounds as CDK2 inhibitors
WO2021072232A1 (en) 2019-10-11 2021-04-15 Incyte Corporation Bicyclic amines as cdk2 inhibitors
CA3172750A1 (en) * 2020-03-23 2021-09-30 Ge Hyeong Lee Novel pyrimidine derivative, and composition for preventing or treating neurodegenerative diseases and cancer, comprising same
US11833155B2 (en) 2020-06-03 2023-12-05 Incyte Corporation Combination therapy for treatment of myeloproliferative neoplasms
TW202328096A (en) * 2021-08-27 2023-07-16 南韓商柳韓洋行 5-membered heteroaryl-containing aminopyridine compounds as egfr inhibitors

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6514977B1 (en) 1997-05-22 2003-02-04 G.D. Searle & Company Substituted pyrazoles as p38 kinase inhibitors
AU2001291013A1 (en) * 2000-09-15 2002-03-26 Vertex Pharmaceuticals Incorporated Pyrazole compounds useful as protein kinase inhibitors
DE60135676D1 (en) * 2000-12-05 2008-10-16 Vertex Pharma INHIBITORS OF C-JUN N-TERMINAL KINASES (JNK) AND OTHER PROTEIN KINASES
GB0129476D0 (en) * 2001-12-10 2002-01-30 Syngenta Participations Ag Organic compounds

Also Published As

Publication number Publication date
US20030144309A1 (en) 2003-07-31
US6884804B2 (en) 2005-04-26
WO2002092573A2 (en) 2002-11-21
WO2002092573A3 (en) 2004-01-22
CA2446864C (en) 2011-02-15
EP1404669A2 (en) 2004-04-07
AU2002308748A1 (en) 2002-11-25
JP4316893B2 (en) 2009-08-19
JP2004534754A (en) 2004-11-18

Similar Documents

Publication Publication Date Title
CA2446864A1 (en) Inhibitors of src and other protein kinases
AU2016299485B2 (en) 1,3,4-oxadiazole amide derivative compound as histone deacetylase 6 inhibitor, and pharmaceutical composition containing same
DE60026509T2 (en) CHINOLINE DERIVATIVES AS MEK ENZYME INHIBITORS
CN101528232B (en) Hepatitis c virus inhibitors
CA2353460C (en) Carboxylic acids and carboxylic acid isosteres of n-heterocyclic compounds
TWI235752B (en) Inhibitors of c-JUN N-terminal kinases (JNK) and other protein kinases
DE69838515T2 (en) AMINOTHIAZOLE FOR INHIBITING CYCLINE-DEPENDENT KINASES
CN103987707B (en) The base heterocyclic radical benzamide compound of pyrazoles 4 and application method
TW202019900A (en) Ptpn11 inhibitors
CN114437105A (en) Inhibitors of receptor interacting protein kinase 1
DE69531502D1 (en) MONOAMIDE, DIAMIDE, THIOL CONTAINING METAL-CHELATING COMPOUNDS
CN105085429B (en) Aromatic heterocyclic derivative and application thereof in medicines
AU2019203282A1 (en) Dipeptide and tripeptide epoxy ketone protease inhibitors
CN102015705A (en) Fused heterocyclic derivative and use thereof
CN106661031B (en) Pyrrolopyrimidine compounds or its salt, pharmaceutical composition and application containing it
CN110234656A (en) Extracellular nucleotides enzyme inhibitor and its application method
CN101558059A (en) Hepatitis C virus inhibitors
CN102153540A (en) Chemokine receptor binding heterocyclic compounds with enhanced efficacy
CN101534829A (en) Hepatitis C virus inhibitors
WO1997017329A1 (en) Quinoline derivatives and quinazoline derivatives inhibiting autophosphorylation of growth factor receptor originating in platelet and pharmaceutical compositions containing the same
WO2000068200A1 (en) Quinoline derivatives as inhibitors of mek enzymes
DE69635114T2 (en) PROTEIN FUNGAL SYN-TRANSFERASE INHIBITORS IN COMBINATION WITH HMGCOA REDUCTASE INHIBITORS FOR THE TREATMENT OF AIDS
CN105399698B (en) Aromatic heterocyclic derivatives and its application in drug
DE69612540T2 (en) Use of hydantoin derivatives for the manufacture of a medicament for the treatment of diseases related to active oxygen and free radicals
CN103298817A (en) Novel sulfamide piperazine derivatives as protein tyrosine kinase inhibitors and pharmaceutical use thereof

Legal Events

Date Code Title Description
EEER Examination request
MKLA Lapsed

Effective date: 20140516